ImmusanT (NEXPEP) present results of Phase 1 Coeliac vaccine

May 8, 2011

Bob Anderson (CEO Nexpep Pty Ltd), CSO ImmusanT Inc., discussed the results of phase 1 Nexvax2 study at the recent Digestive Diseases Week conference in Chicago, Illinois. For the study Medicines Development provided a full time Development Manager and a part time Project Leader to supplement Nexpep’s own internal resources.